Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

10 richest women in India in 2024

<keyword id="6354512" type="General" weightage="100" keywordseo="infosys" source="Orion">Infosys</keyword> on Thursday announced the retirement of <keyword id="1440" type="General" weightage="80" keywordseo="kiran" source="Orion">Kiran</keyword> Mazumdar-Shaw as <keyword id="6390711" type="General" weightage="80" keywordseo="independent" source="Orion">Independent</keyword> Director from its Board, effective March 22, 2023, upon completion of her tenure. Accordingly, the Board has appointed D <keyword id="120337" type="General" weightage="80" keywordseo="sundaram" source="Orion">Sundaram</keyword> as the Lead Independent Director of the Company, effective Thursday based on the recommendation of the 'Nomination and Remuneration Committee'. Sundaram has been on the Board of Infosys since 2017. Sundaram serves on the Audit Committee, Risk Management Committee, <keyword id="16919243" type="General" weightage="50" keywordseo="stakeholders-relationship-committee" source="Orion">Stakeholders Relationship Committee</keyword>, Nomination and Remuneration Committee, and Cybersecurity Risk Sub-Committee. "We profusely thank Kiran for having been such an integral member of the Infosys family, providing valuable guidance and leadership to the Board over the years. I am personally very grateful to her as she has been a tremendous ally and amazing colleague on the Board, ever since I re-joined Infosys in August 2017," chairman of Infosys Nandan Nilekani, said. "We also congratulate Sundaram on being appointed as Lead Independent Director and look forward to his continued insight and steadfast support as Infosys continues its growth and transformation journey," Nilekadded. Kiran Mazumdar-Shaw was appointed to the Infosys' Board as an Independent Director in 2014, and as Lead Independent Director in 2018. She also served as the Chairperson of the 'Nomination &amp; Remuneration Committee' and 'CSR Committee', and as a member of the 'Risk Management and ESG Committees' of the Board. "The Board places on record its appreciation for Ms Shaw's invaluable contribution, guidance, and strategic vision, which has helped the Company build and execute a resilient growth strategy," Infosys said in a release. Kiran Mazumdar-Shaw is the Chairperson and Managing Director of Biocon Limited, a biotechnology company based in Bangalore, India. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/news/former-idbi-gm-conspired-with-vijay-mallya-over-short-term-loan-to-kingfisher-airlines-cbi/articleshow/98936880.cms">Former IDBI GM conspired with Vijay Mallya over short term loan to Kingfisher Airlines: CBI</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/finance/banks/news/fm-nirmala-sitharaman-likely-to-meet-psu-banks-heads-on-saturday/articleshow/98936889.cms">FM Nirmala Sitharaman likely to meet PSU banks heads on Saturday</a>

Kiran Mazumdar-Shaw to retire from Infosys board

Global biopharmaceuticals company <keyword id="6358361" type="General" weightage="100" keywordseo="biocon" source="Orion">Biocon</keyword> on Wednesday reported 23 per cent rise in revenue for the first quarter of financial year 2023, at Rs 2,217 crore. "We have had a strong start to the year. At a consolidated level, YoY revenues grew 23 per cent backed by robust growth in both <keyword id="6359687" type="General" weightage="50" keywordseo="biosimilars" source="Orion">Biosimilars</keyword> (29 per cent) and Generics (19 per cent). Core earnings before interest, taxes, depreciation, and amortisation (EBITDA) grew 25 per cent and margin improved to 31 per cent compared to 30 per cent in Q1FY22 and net profit grew 71 per cent to Rs 144 crore. "Our financial performance this quarter includes the impact of annual increments in personnel costs as well as increased input and freight costs, pursuant to pandemic and geopolitical disruptions of global supply chains. "All our three businesses are poised for the next phase of strong and sustainable growth which has been challenged during the two years of the Covid-19 pandemic," <keyword id="14575168" type="General" weightage="50" keywordseo="biocon-and-biocon-biologics-executive" source="Orion">Biocon and Biocon Biologics Executive</keyword> <keyword id="10034873" type="General" weightage="20" keywordseo="chairperson-kiran-mazumdar-shaw" source="Orion">Chairperson Kiran Mazumdar-Shaw</keyword> said. Sales of Glargine in the US, and key biosimilars in emerging markets were the main drivers for <keyword id="14245336" type="General" weightage="50" keywordseo="biocon-biologicals" source="Orion">Biocon Biologicals</keyword>' strong performance. <keyword id="10493627" type="General" weightage="50" keywordseo="biocon-biologics-ltd" source="Orion">Biocon Biologics Ltd</keyword> Managing Director <keyword id="287851" type="General" weightage="50" keywordseo="arun-chandavarkar" source="Orion">Arun Chandavarkar</keyword> said: "Initiation of global clinical trials for two monoclonal antibodies and advancement of our other pipeline assets led to a 120 per cent increase in our research and development investments this quarter. Whilst this impacts EBITDA in the near term, such investments will create a strong portfolio to secure our future growth. "Our strategic alliance with Serum Institute Life Sciences for vaccines and the acquisition of Viatris' global biosimilars business are on track for closure in the second half of this calendar year." SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/india/news/reduction-in-rice-cereals-sown-area-worrisome-bank-of-baroda/articleshow/93175801.cms">Reduction in rice, cereals sown area worrisome: Bank of Baroda</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/tech/news/oppo-pad-air-review-sleek-and-stylish-but-short-on-power/articleshow/93165775.cms">Oppo Pad Air review: Sleek and stylish but short on power</a>

Biocon Q1FY23 revenue up 23% at Rs 2,217 cr

<ul><li><keyword id="6379793" type="General" weightage="100" keywordseo="falguni-nayar" source="Orion">Falguni Nayar</keyword> is the richest self-made billionaire with a net worth of ₹57,520 crore.</li><li>However, <keyword id="1490249" type="General" weightage="20" keywordseo="Roshni-Nadar-Malhotra" source="Orion">Roshni Nadar Malhotra</keyword> of HCL Technologies is the wealthiest woman, as per Kotak Private Banking Hurun list.</li><li>Around 25 new women have entered into the list this year, says the report.</li></ul>It’s beauty over biotech as Falguni Nayar overtook Biocon’s <keyword id="6413985" type="General" weightage="20" keywordseo="kiran-mazumdar-shaw" source="Orion">Kiran Mazumdar-Shaw</keyword> as India’s richest self-made woman with a wealth of ₹57,520 crore, as per Kotak Private Banking Hurun’s list of India’s wealthiest women. Nayar’s ranking went up nine places in the list, after the company she founded, Nykaa, went public last year. Roshni Nadar Malhotra of HCL Technologies however retained her title as the wealthiest woman on the list with ₹84,330 crore, for the second year in a row. Around 25 new women have entered into the list this year, says the report. The report further highlights that the cut-off wealth required to feature in the list has almost tripled since last year to ₹300 crore. The women on the 2021 list have an average wealth of around ₹4,170 crore as against ₹2,725 crore in the last year. “Over the years, Indian women are slowly yet surely coming into their own - carving a space for themselves through knowledge, excellence, passion, and empathy,” said <keyword id="14568875" type="General" weightage="80" keywordseo="oisharya-das" source="Orion">Oisharya Das</keyword>, CEO – private banking, <keyword id="46013" type="General" weightage="50" keywordseo="kotak-mahindra-bank" source="Orion">Kotak Mahindra Bank</keyword>. The list is based on the net worth of women as on 31 st December, 2021. <cmsannotation type="cmsannotation" annotationid="More younger women are becoming self-made billionaires" comment="subhead" text="More younger women are becoming self-made billionaires">More younger women are becoming self-made billionaires</cmsannotation> Even though the founder of Biocon, Shaw, was displaced — her sector pharmaceuticals too saw the most number of new entrants, followed by healthcare and consumer goods. 9 out 20 women under the age of 40 years or younger category are self-made, according to the report. Three professional managers also made it to the list. Pepsico’s <keyword id="6421975" type="General" weightage="80" keywordseo="indra-nooyi" source="Orion">Indra Nooyi</keyword> is the richest professional manager, with a wealth of ₹5,040 crore. And, 33-year-old Kanika Tekriwal of Jetsetgo is the youngest self-made woman. “Women-led wealth creation directly improves women’s employment, corresponding families, and society. Inclusion of women, who represent 50% of India’s population in the workforce or wealth creation, cuts across societal barriers,” said <keyword id="2672295" type="General" weightage="80" keywordseo="anas-rahman-junaid" source="Orion">Anas Rahman Junaid</keyword>, MD and chief researcher at <keyword id="3656834" type="General" weightage="50" keywordseo="hurun-india" source="Orion">Hurun India</keyword>. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/telecom/news/5g-spectrum-auctions-big-money-is-in-but-no-bidding-war-yet/articleshow/93156289.cms">5G spectrum auctions: Big money is in but no bidding war yet</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/tech/apps/news/a-massive-data-breach-in-2020-impacted-3-4-million-paytm-usersheres-how-to-find-out-if-your-data-was-compromised/articleshow/93157246.cms">A massive data breach in 2020 impacted 3.4 million Paytm users – here’s how to find out if your data was compromised</a>

Nykaa’s Falguni Nayar overtakes Kiran Mazumdar Shaw as the richest self-made Indian woman

<ul><li><a href="https://www.businessinsider.in/trendsfestival" data-type="tilCustomLink">Global Trends Festival</a> is one of the world's most prestigious events which will be live from Oct 19-23.</li><li>While nobel laureates, some of the biggest political and corporate icons will provide thought leadership, it's a great platform to network with CXOs from around the world.</li><li><a href="https://www.businessinsider.in/trendsfestival" data-type="tilCustomLink">Global Trends Festival 2020</a> is presented by <a href="https://www.businessinsider.in/trendsfestival" data-type="tilCustomLink"></a><a href="https://aws.amazon.com/" data-type="tilCustomLink">AWS</a>.</li><li>Register for the <keyword id="10088455" type="UNKNOWN" weightage="20" keywordseo="global-trends-festival">Global Trends Festival</keyword> <a href="https://www.businessinsider.in/trendsfestival" data-type="tilCustomLink"></a><a href="https://www.businessinsider.in/trendsform_2020.cms" data-type="tilCustomLink">here</a>.</li></ul> Kiran Mazumdar Shaw is India's richest self-made woman. She started Biocon at the age of 25 and has built it up into the country's largest pharmaceutical company. Her journey to the top was no easy task, but Shaw is known for her thinking and vision. Shaw could foresee the potential and opportunity in the biotech space, and she capitalised on it. Shaw calls herself an "accidental entrepreneur." She wanted to become India's first woman brewmaster. When those plans met with resistance in India, she set her sights on the industrial enzyme-producing business and marched on to conquer the biopharma space in the 90s. In 2014, Biocon was India's first biotech company to go public, and it hit the <a href="https://www.businessinsider.in/thelife/personalities/news/indias-second-richest-woman-kiran-mazumdar-shaw-nearly-doubles-her-wealth-to-4-6-billion-during-the-covid-19-pandemic/articleshow/78569565.cms">$1 billion mark</a> on the day it listed. There has been no looking back since. Kiran Mazumdar Shaw believes that women play an essential role in economic development, and their contribution has been ignored for a long time. "It's a myth to think that women are not bold enough to run daring businesses. It's a myth that all of us have busted time. So, I'm really surprised that the world still doesn't get it," she told <a href="https://www.businessinsider.in/thelife/personalities/news/kiran-mazumdar-shaw-wanted-to-be-a-brewmaster-before-founding-the-largest-biotech-company-in-india/articleshow/74508921.cms">Twitter </a>in an interview earlier this year. A pioneer of the biotech industry in India, Shaw has been conferred upon with Padma Shri and the Padma Bhushan. She believes that entrepreneurship is not about making the moolah but having a purpose, and one must always think about giving back to society. In fact, Shaw can tell the Covid-19 story as a survivor and a healer. After all, she has the first-hand experience — as the 67-year old tested positive in mid-August and recovered by the end of the month. And her $7 billion company, Biocon's repurposed drug, Itolizumab, is used to treat the dreaded virus for emergency cases. However, the drug is not a part of the government's clinical management protocol for COVID-19 treatment yet. At the Global Trends Festival 2020, Shaw will share insights on why entrepreneurs must be risk-takers, her journey as a businesswoman, and unlocking India's suppressed potential. SEE ALSO: <a href="https://www.businessinsider.in/trendsfestival" data-type="tilCustomLink"></a><a href="https://www.businessinsider.in/business/news/guenter-butschek-will-speak-about-the-much-needed-electric-push-towards-a-greener-future-at-the-global-trends-festival/articleshow/78642212.cms" data-type="tilCustomLink">Guenter Butschek will speak about the much needed electric push towards a greener future at the Global Trends Festival</a> <a href="https://www.businessinsider.in/trendsfestival" data-type="tilCustomLink"></a><a href="https://www.businessinsider.in/business/news/hear-and-learn-from-byju-raveendran-the-man-who-made-online-classes-fun-years-before-covid-at-the-global-trends-festival-2020/articleshow/78641694.cms" data-type="tilCustomLink">Hear and learn from Byju Raveendran, the man who made online classes fun, years before COVID, at the Global Trends Festival 2020</a> <a href="https://www.businessinsider.in/trendsfestival" data-type="tilCustomLink"></a><a href="https://www.businessinsider.in/business/news/dont-miss-rana-daggubati-speak-about-the-future-of-storytelling-at-the-global-trends-festival-2020/articleshow/78630087.cms" data-type="tilCustomLink">Don’t miss Rana Daggubati speak about the future of storytelling at the Global Trends Festival 2020</a>

Catch Kiran Mazumdar Shaw at the Global Trends Festival 2020, speak about unlocking India's suppressed potential

<ul><li>Half of the billionaires, including Mukesh Ambani, Radhakishan Damani, Gautam Adani, Cyrus Poonawalla, saw significant gains in their wealth. </li><li>The biggest percentage gainer was 67-year old Kiran Mazumdar-Shaw, Biocon founder and the second richest woman in India. </li><li>While Biocon has joined the race to discover the vaccine, Shaw was not immune to COVID-19. She tested positive in August and recovered in a fortnight. </li></ul>India’s super-rich club of 100 people has added nine new faces and about $88 billion collectively during the coronavirus pandemic — which is assumed to be far worse than the Great Depression. Half of the billionaires, including Mukesh Ambani, Radhakishan Damani, Gautam Adani, Cyrus Poonawalla saw significant gains — taking the collective net worth of 100 billionaires to $517.5 billion, <a href="https://www.forbes.com/sites/naazneenkarmali/2020/10/07/indias-100-richest-2020-collective-net-worth-of-countrys-richest-rose-14-despite-pandemic/#2cf4d5e93da4">Forbes reported. </a> The biggest percentage gainer was 67-year old Kiran Mazumdar-Shaw, Biocon founder and the second richest woman in India. Her wealth has nearly doubled from $2.38 billion in 2019 to $4.6 billion in 2020 — a whopping 93.28% gain among India's 100 richest. She is one of the only five women billionaires in India. <keyword id="55796" type="PERSON" weightage="20" keywordseo="Kiran-Mazumdar-Shaw">Kiran Mazumdar Shaw</keyword> started her Indian-based pharma company about 42 years ago with merely two employees and $500 funds. However, it was not until 2014 that her company became a publicly-traded entity. It touched the $1billion mark on the very day it listed. Over the past decade, Biocon has grown by leaps and bounds to become a $5 billion company. In just the last 12 months, Biocon’s share price has surged 99% from ₹233 in October 2019 to ₹464.70 currently. <div type="image" title="Biocon11" msid="78569590" hostid="261"></div> While her company has joined the race to discover a vaccine to fight the virus, Shaw wasn’t immune to it. On August 16, she tested positive for COVID-19 and recovered 15 days later. Shaw has been vocal about leveraging science to contain the virus. Three months after coronavirus broke out in India, Biocon announced that it would launch biologic drug Itolizumab for the treatment of moderate to severe COVID-19 patients at a price of around ₹8,000 per vial. The pharmaceutical is set to begin the phase-4 trials of the potential drug. Well, Shaw might have gained the most, but Mukesh Ambani’s record gains have left everyone behind. He remains India’s richest man for the 13th year in the running and leads by a large margin. Ambani added $37.3 billion to his fortune, thanks to the trail of investments in Reliance Jio and his retail venture. Jio alone got $20 billion investments from investors like Google, Facebook, and Microsoft. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/corporates/news/tcs-beats-accenture-to-become-the-worlds-most-valuable-it-services-company/articleshow/78566487.cms">TCS beats Accenture to become the world’s most valuable IT services company — but this not the first time it has raced ahead</a>

India’s second richest woman nearly doubles her wealth to $4.6 billion during the COVID-19 pandemic

India’s richest women as per Hurun list: Kiran Mazumdar Shaw and Smita Crishna on top

<ul><li>On June 5, Biocon’s Executive <keyword id="9348685" type="PERSON" weightage="20" keywordseo="chairperson-kiran-mazumdar-shaw">Chairperson Kiran Mazumdar Shaw</keyword> was named as <keyword id="9348456" type="UNKNOWN" weightage="20" keywordseo="ey-world-entrepreneur-of-the-year">EY World Entrepreneur of the Year</keyword> 2020. </li><li>With this, she joined Uday Kotak of Kotak Mahindra Bank and Narayana Murthy of Infosys, who were awarded with this honour in 2014 and 2005, respectively. </li><li>She founded the India-based pharma company Biocon with merely two employees and funds worth $500. </li><li>In 2014, Biocon became the first biopharma company to be a publicly-traded entity and the second company to touch the $1 billion mark on the very first day of the listing.</li></ul>In 1978, <keyword id="55796" type="PERSON" weightage="20" keywordseo="Kiran-Mazumdar-Shaw">Kiran Mazumdar Shaw</keyword> founded the India-based pharma company Biocon with merely two employees and funds worth $500. 42 years later, Shaw has been named as <keyword id="9348684" type="UNKNOWN" weightage="20" keywordseo="ey-world-entrepreneur">EY World Entrepreneur</keyword> of the Year 2020. <div type="twitter" handle="EY_EOY" handlename="EY EOY" image="http://pbs.twimg.com/profile_images/877518155282878464/HTnSrpib_normal.jpg" favoritecount="302" retweetcount="123" status="Congratulations to @kiranshaw, Executive Chairperson of India-based @Bioconlimited who is named EY World Entreprene… https://t.co/eYxchprTNh" createdat="1591297093000" id="1268618074879438853"></div> With this, she has joined the likes of Uday Kotak of Kotak Mahindra Bank and Narayana Murthy of Infosys, who were awarded with this honour in 2014 and 2005 respectively. The virtual award ceremony was held on June 5 — and she was chosen from over 46 entrepreneurs from 41 countries. “She has built India's largest biopharmaceutical company on a foundation of compassionate capitalism and putting patient needs before profits,” Chair of the EY World Entrepreneur Of The Year judging panel <a href="https://www.prnewswire.com/in/news-releases/dr-kiran-mazumdar-shaw-from-india-named-ey-world-entrepreneur-of-the-year-tm-2020-883966722.html">said</a>. An aspiring Brewmaster who opened a bio-enzymes company <div type="image" title="eea0f7895182bcc364abaeda35e570da" msid="76208305" hostid="261"></div> Kiran, who graduated from Australia in 1975 wanted to work as a Brewmaster — a person who looks after everything that goes in the process of making a beer. Little did she know, the brewing industry — which is highly male-dominated in India — will not accept a woman in the role. But, that did not stop her. Two years down the line, she started Biocon in a rented house in Bengaluru where they produced the bio enzymes in the garage. A year of struggle and Biocon became the first such company in India that exported enzymes to other countries like the US and Europe. Years later, in 2004, she came up with <keyword id="1829392" type="COMPANY" weightage="20" keywordseo="Biocon-Foundation">Biocon Foundation</keyword> — which aims to provide healthcare and sanitation facilities and diagnosis and treatment of cancer and other non-communicable diseases to weaker sections of the society. Bicon goes public <div type="image" title="06c05f1aefb71a5e6abe2fa9b1bd87fa" msid="76208327" hostid="261"></div> In 2014, Biocon became the first biopharma company to be a publicly-traded entity and the second company to touch the $1 billion mark on the very first day of the listing. Over the years, the bio-enzymes major — which is now one of the prominent biotech giants in Asia — grew multifold to become a <a href="https://www.businessinsider.in/stock-market/news/biocon-share-price-falls-after-earnings-and-mutual-funds-stake-in-the-stock/articleshow/75754048.cms">$5 billion company</a>. Today, Biocon provides healthcare requirements like insulin for diabetes, biosimilars for those fighting cancer, arthritis and other severe diseases. The company reported revenue worth $800 million, as of FY19 and employees more than 11,000 people. In fact, Biocon has created its mark where other pharma giants are struggling and has a presence in over 120 countries. That includes fermentation-based molecules, human insulin, contract research services and more. That may be because of the affordability of the products. In September 2019, Biocon announced the supply of a special kind of insulin to middle income companies on low prices — in fact, less than a third of the current prices. Meanwhile, Shaw has been an angel investor for a lot of startups in the healthcare domain including those in areas like breast cancer screening, chemotherapy and others. In times of the global pandemic While the world is waiting with bated breath for a vaccine to treat coronavirus, Shaw believes that it will take <a href="https://www.businessinsider.in/science/health/news/biocon-chairperson-kiran-mazumdar-shaw-says-indias-covid-19-vaccines-will-enter-clinical-trial-in-9-months/articleshow/75591805.cms">at least nine months for the COVID-19 vaccine to enter clinical trials</a> in India. She also said that there will be multiple waves before the coronavirus curve flattens as community spread remains a key challenge in India. See also: <a href="https://www.businessinsider.in/business/news/mubadala-to-buy-1-85-pc-stake-in-jio-platforms-for-rs-9093-6-cr/articleshow/76205654.cms?upcache=2">Abu Dhabi's Mubadala to buy 1.85% stake in Ambani's Jio Platforms for ₹9093.6 crore</a> <a href="https://www.businessinsider.in/policy/foreign-policy/news/a-former-diplomat-explains-why-four-agreements-will-take-india-and-australia-ties-to-the-next-level/articleshow/76206931.cms">Beyond ‘khichdi’ and ‘samosa’ ⁠— a former diplomat explains why four agreements will take India and Australia ties to the next level</a>

Biocon’s Kiran Mazumdar Shaw, who debuted in the pharma industry with two employees and $500 becomes EY World Entrepreneur of the Year 2020

<ul><li>In recent years, mainstream investors have been incorporating a gender lens while making investment decisions and have started recognizing the strength of women as a market force. </li><li>However, a Global Gender Gap Report 2020 by the World Economic Forum said gender parity would not be attained for nearly a century, globally. </li><li>Speaking at the Global Trends Festival 2020, leading women business leaders have raised the need to break barriers and bring about faster, sustainable change to empower more women. </li></ul><keyword id="8816177" type="UNKNOWN" weightage="20" keywordseo="Gender-Lens-Investing">Gender lens investing</keyword> is gaining ground across emerging economies over the past few years, but it still has a long way to go when it comes to India. A relatively new concept introduced around a decade ago, gender lens investing is based on <a href="https://www.bsr.org/en/our-insights/blog-view/how-gender-lens-investing-can-transform-your-impact-strategy">investing </a>in a women-founded business or a gender-diverse company that promotes equality and women's empowerment and provides improved financial returns. In 2018, a McKinsey report suggested that India — then the world's fastest-growing economy — could add over $770 billion to its GDP by 2025 by ensuring equal opportunities for women. And that's the need of the hour — the imperative need for faster change in the workforce landscape. Speaking at Business Insider'sInsider's Global Trends Festival 2020 — Biocon's <keyword id="55796" type="PERSON" weightage="20" keywordseo="Kiran-Mazumdar-Shaw">Kiran Mazumdar Shaw</keyword>, Apollo Hospital's Dr <keyword id="189907" type="PERSON" weightage="20" keywordseo="Sangita-Reddy">Sangita Reddy</keyword>, Piramal Enterprises' <keyword id="192486" type="PERSON" weightage="20" keywordseo="Nandini-Piramal">Nandini Piramal</keyword>, and Kalaari Capital's <keyword id="1397790" type="PERSON" weightage="20" keywordseo="Vani-Kola">Vani Kola</keyword> — shared how women entrepreneurs can break the barriers and how investors can shape the market for better. <div type="twitter" handle="BiIndia" handlename="Business Insider India🇮🇳" image="http://pbs.twimg.com/profile_images/1232926719016718336/sfffJHNV_normal.jpg" favoritecount="0" retweetcount="1" status="#LIVEnow | @drsangitareddy on women in India, their representation in the workforce and more.@awscloud presents t… https://t.co/Wvv7PCVE6A" createdat="1603196161000" id="1318526381551013889"></div> "Nearly half of India's potential workforce is underutilized and while the pandemic has truly brought to the fore the word ‘unprecedented,’ one thing is very clear: the change is inevitable," Sangita Reddy, FICCI President and joint MD of Apollo Hospitals said. Unlocking India’s suppressed potential <div type="twitter" handle="BiIndia" handlename="Business Insider India🇮🇳" image="http://pbs.twimg.com/profile_images/1232926719016718336/sfffJHNV_normal.jpg" favoritecount="2" retweetcount="1" status="#Watch | &quot;In most of the startups the senior leadership, very small number are women&quot;: @VaniKola at the… https://t.co/XpqaRX6C8B" createdat="1603197228000" id="1318530856781193216"></div><a href="https://www.weforum.org/reports/gender-gap-2020-report-100-years-pay-equality">A Global Gender Gap Report 2020 </a> by the World Economic Forum said gender parity would not be attained for nearly a century, globally. When it comes to India, the gender gap has been deeply rooted for decades. And since 2006, the gap has only widened. Until 2018, three in <a href="https://www.indiaspend.com/3-in-4-indian-women-dont-work-can-skilling-and-guaranteed-jobs-change-that-38932/">every four women in India did not work</a> — indicating one of the lowest participation rates in the world. While India’s GDP grew from 2000 to 2019, women’s participation in the workforce has <a href="https://economictimes.indiatimes.com/news/company/corporate-trends/how-indias-workforce-participation-rate-of-women-has-sharply-declined-over-the-years/articleshow/74531505.cms">declined </a>sharply. They <a href="https://www.worldbank.org/en/news/speech/2018/03/17/women-indias-economic-growth#:~:text=At%2017%25%20of%20GDP%2C%20the,could%20join%20the%20work%20force.">account </a>for only 17% of the total GDP output. <table style="border-width: initial; border-style: none; width: 468pt; table-layout: fixed;"></colgroup><tbody><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Year </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Women’s participation in workforce </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">2000 </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">30.4% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">2005 </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">32% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">2010 </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">23% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">2015 </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">23.5% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">2019 </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">23.4% </td></tr></tbody></table>Source: <a href="https://economictimes.indiatimes.com/news/company/corporate-trends/how-indias-workforce-participation-rate-of-women-has-sharply-declined-over-the-years/articleshow/74531505.cms">World Bank</a> Moreover, women in India earn only a fifth of men’s income. There are <a href="https://blogs.imf.org/2020/03/03/on-board-with-more-women-in-leadership/">merely 13%</a> of women in leadership positions. Furthermore, women are <a href="https://www.livemint.com/companies/start-ups/why-women-entrepreneurs-are-missing-from-india-s-startup-story-11582267821850.html">missing </a>from India’s buzzing startup world too. <div type="image" title="WORLD BANK 2020 Data" msid="78783296" hostid="261"></div> “I think what we have missed as women or as perceiving women in the workplace is the equitable recognition in terms of the roles they play. We always undervalue them because we think a woman can be paid lower. In an organisation like ours (Biocon), we pay for the role and not gender and that has made a huge difference to us as a company” Kiran Mazumdar Shaw, Founder and CEO, Biocon, said at the Global Trends Festival 2020. The need to bring about equal responsibilities at home The other deterrent is the lack of work-life balance. Thousands of women who are a part of the formal workforce also run a household — making it difficult for them to concentrate and excel at work. Nandini Piramal believes that there’s a need to change the expectations and share responsibilities at home. And this COVID-19 pandemic has brought this issue to the forefront as well. <div type="twitter" handle="BiIndia" handlename="Business Insider India🇮🇳" image="http://pbs.twimg.com/profile_images/1232926719016718336/sfffJHNV_normal.jpg" favoritecount="2" retweetcount="2" status="@kiranshaw @awscloud @HospitalsApollo @Bioconlimited @Kalaari @VaniKola @BIPolska @BIJapan @BIDeutschland @BIEspana… https://t.co/X4JepuqTO7" createdat="1603197084000" id="1318530255259201537"></div>“For the first time a lot of people did not have any help at home. For the first time, I know, my male colleagues were told to run the household together — to pitch in and make sure kids go to school, the washing is done and the food made. If as a woman you are dealing with home, children and work and you want to succeed in all of them then there are not many hours in the day. So we have to change how we bring up our men,” Piramal said. The lens of gender investing In recent years, mainstream investors have been incorporating a gender lens while making investment decisions and have started recognizing the strength of women as a market force. In India, there are some investors like <a href="https://yourstory.com/2019/01/gray-matters-capital-india-investment">Gray Matters Capital </a>and Innoven Capital hold similar strategies while investing in startups. However, Innoven Capital says the number o<a href="https://www.livemint.com/companies/start-ups/why-women-entrepreneurs-are-missing-from-india-s-startup-story-11582267821850.html">f funded</a> startups with at least one female co-founder declined from 17% in 2018 to 12% in 2019. “We have to create systematic programmes. In the US, Melinda Gates has a fund for women entrepreneurs. Early indication is that it has actually been successful. We also have to work on increasing the base, which allows women to think about leadership roles,” Vani Kola, Kalaari Capital said. Kola added there’s still a lot of work to be done to ensure ground-level entrepreneurship. Moreover, there’s also a need to raise awareness about investing in women leaders. While the situation has been challenging for first-time women entrepreneurs, what also can make the difference is the way women present their ideas to a venture capitalist. <div type="twitter" handle="BiIndia" handlename="Business Insider India🇮🇳" image="http://pbs.twimg.com/profile_images/1232926719016718336/sfffJHNV_normal.jpg" favoritecount="10" retweetcount="4" status="#WATCH | &quot;Do not have self-doubt&quot;: @kiranshaw's message to women entrepreneurs.@awscloud presents the Business In… https://t.co/md4e0KMd5x" createdat="1603197432000" id="1318531714059128832"></div> “The difference between men and women when they present to a venture capitalist is that a man makes a small idea seem very big and a woman, unfortunately, dwarfs her big idea. I say why are you like that? This is a great idea but you are making it sound as if it's trivial,” said Kiran Mazumdar Shaw. She believes that women should rid themselves of this self-doubt and present their ideas with more confidence. Gender lens investing — what needs to be done “I really believe if there can be a small carve-out to focus on women development and women empowerment -- I mean that in terms of financial inclusion -- a lot of miracles can happen. I think everyone needs a helping hand, not a handout. If we can create it that way a lot can happen,” Kola said. Vani Kola suggests dedicating a platform specifically for women entrepreneurs, like the one established by the Telangana government, which can help them get through the beginning stages and provide them confidence. “If we can find something to incubate and support that early start and the capacity to have confidence, we can create an effect,” she added. With steps like ensuring more leadership roles for women and investments with a gender lens focus, India can push for more women empowerment to help transform the economy, build an equal society and a better world. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/thelife/news/luxury-icons-sabyasachi-and-oberoi-open-up-about-their-perfectionist-quirks-like-checking-the-color-of-egg-yolks-and-slashing-clothes-so-they-cant-hit-the-edit-table/articleshow/78771113.cms">Luxury icons Sabyasachi and Oberoi open up about their 'perfectionist quirks' like checking the color of egg yolks and slashing clothes so they can’t hit the edit table</a>

What is gender lens investing? Sangita Reddy, Kiran Mazumdar Shaw, Nandini Piramal, and Vani Kola share their thoughts

New Delhi, Apr 18 () COVID-19 will reboot the world into virtual reality and after the crisis, work from home models are likely to continue and business travel is likely to be curtailed as virtual meetings have proved to be just as effective, Biocon Executive Chairperson Kiran Mazumdar-Shaw on Saturday said. In a blog post, she said mobile and internet banking have also seen a surge since the viral outbreak. The new world order will now become a virtual reality, she added. "The seismic events unleashed by the COVID-19 pandemic will have a powerful impact on the world we live in, changing it in ways we had never imagined were possible. The economic damage is likely to be unprecedented," Mazumdar-Shaw said. The world economy, worth USD 90 trillion at the start of the current financial year, would have lost USD 5 trillion and moved into recession by the time the next financial year starts, she added. "COVID-19 is the reboot button that will trigger a system-wide overhaul. A year from now, the world we will live in will be very different. It will impact how we live, how we work, and how we use technology," Mazumdar-Shaw said. To quote a recent McKinsey report, "In this unprecedented new reality, we will witness a dramatic restructuring of the economic and social order in which business and society have traditionally operated," she added. This COVID-19 outbreak is a lesson that technology has many faces and being besotted with only one application of computational science is dangerous, Mazumdar-Shaw said. "For humanity to survive, we will need a multi-disciplinary approach to advancing science and technology, combining biotechnology, biomedical technologies, biological sciences, environmental sciences, etc," she added. The novel coronavirus has exposed the huge shortcomings in public healthcare systems, especially in developed countries where they have largely remained static since World War II, she added. Mazumdar-Shaw said the governments will have to bring in policies to address essential healthcare infrastructure, strategic reserves of key supplies, and contingency planning for medical equipment, diagnostics, drugs and vaccines. "COVID-19 will also cast a long shadow on our social and cultural lives," she added. What repercussions these changes will have on the shape of human society only time can tell, Mazumdar-Shaw said. The post-COVID-19 world is unlikely to look like the "normal" we have grown accustomed to in the recent years, she added. "Ultimately, the greatest lesson that COVID-19 can teach humanity is that we are all in this together, that what affects a single person anywhere affects everyone everywhere, that as homo sapiens we need to think and act unitedly rather than worrying about race, ethnicity, nationality, religion, economic status, and such artificial groupings," Mazumdar-Shaw said. AKT HRS

COVID-19 will reboot world into virtual reality: Kiran Mazumdar-Shaw

<ul><li><keyword id="6358361" type="DEFINITION" weightage="20" keywordseo="biocon">Biocon</keyword>’s subsidiary company <keyword id="8144461" type="UNKNOWN" weightage="20" keywordseo="Biocon-Biologics">Biocon Biologics</keyword> has raised $30 million from <keyword id="154226" type="CITY" weightage="20" keywordseo="Tata-Capital">Tata Capital</keyword> Growth Fund, valuing the company at $3.5 billion.</li><li>Biocon’s share price jumped by almost 2% as the news of the funding came in. </li><li>Biocon Biologics claims to hold one of the world’s largest <keyword id="6359687" type="UNKNOWN" weightage="20" keywordseo="biosimilars">biosimilars</keyword> portfolios.</li></ul>Biocon’s subsidiary company Biocon Biologics has raised $30 million from Tata Capital Growth Fund, valuing the company at $3.5 billion. With the equity transaction, Tata Capital will get a 0.85% stake in Biocon Biologics. Biocon’s share price jumped by almost 2% as the news of the funding came in. <div type="image" title="biocon" msid="77277164" hostid="261"></div> “This equity infusion is the next step in our journey of unlocking value. Through prudent investments in R&amp;D and high-quality manufacturing infrastructure we are confident of achieving our aspiration of serving 5 million patients through our biosimilars portfolio and achieving a target revenue of $1 billion in FY22,” said Dr. Christiane Hamacher, CEO, Biocon Biologics in a statement. Biocon Biologics claims to hold one of the world’s largest biosimilars portfolios. Biosimilars are medical products that are highly similar to already existing and approved drugs, and they contribute heavily to the company’s revenue. <table style="border-width: initial; border-style: none;"></colgroup><tbody><tr><td style="border-left:solid #000000 0.9960975000000001pt;border-right:solid #000000 0.9960975000000001pt;border-bottom:solid #000000 0.9960975000000001pt;border-top:solid #000000 0.9960975000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Particulars </td><td style="border-left:solid #000000 0.9960975000000001pt;border-right:solid #000000 0.9960975000000001pt;border-bottom:solid #000000 0.9960975000000001pt;border-top:solid #000000 0.9960975000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Revenue Growth </td><td style="border-left:solid #000000 0.9960975000000001pt;border-right:solid #000000 0.9960975000000001pt;border-bottom:solid #000000 0.9960975000000001pt;border-top:solid #000000 0.9960975000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Contribution to Revenue </td></tr><tr><td style="border-left:solid #000000 0.9960975000000001pt;border-right:solid #000000 0.9960975000000001pt;border-bottom:solid #000000 0.9960975000000001pt;border-top:solid #000000 0.9960975000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Generics </td><td style="border-left:solid #000000 0.9960975000000001pt;border-right:solid #000000 0.9960975000000001pt;border-bottom:solid #000000 0.9960975000000001pt;border-top:solid #000000 0.9960975000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">16% </td><td style="border-left:solid #000000 0.9960975000000001pt;border-right:solid #000000 0.9960975000000001pt;border-bottom:solid #000000 0.9960975000000001pt;border-top:solid #000000 0.9960975000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">35.40% </td></tr><tr><td style="border-left:solid #000000 0.9960975000000001pt;border-right:solid #000000 0.9960975000000001pt;border-bottom:solid #000000 0.9960975000000001pt;border-top:solid #000000 0.9960975000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Biosimilars </td><td style="border-left:solid #000000 0.9960975000000001pt;border-right:solid #000000 0.9960975000000001pt;border-bottom:solid #000000 0.9960975000000001pt;border-top:solid #000000 0.9960975000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">19% </td><td style="border-left:solid #000000 0.9960975000000001pt;border-right:solid #000000 0.9960975000000001pt;border-bottom:solid #000000 0.9960975000000001pt;border-top:solid #000000 0.9960975000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">40.90% </td></tr><tr><td style="border-left:solid #000000 0.9960975000000001pt;border-right:solid #000000 0.9960975000000001pt;border-bottom:solid #000000 0.9960975000000001pt;border-top:solid #000000 0.9960975000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Research Services </td><td style="border-left:solid #000000 0.9960975000000001pt;border-right:solid #000000 0.9960975000000001pt;border-bottom:solid #000000 0.9960975000000001pt;border-top:solid #000000 0.9960975000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">0 </td><td style="border-left:solid #000000 0.9960975000000001pt;border-right:solid #000000 0.9960975000000001pt;border-bottom:solid #000000 0.9960975000000001pt;border-top:solid #000000 0.9960975000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">24.90% </td></tr></tbody></table> “The investment brings together 150+ years of brand equity of Tata’s and a very strong R&amp;D based entrepreneur in Dr Kiran Mazumdar-Shaw with a golden track record of conceptualizing, investing and creating billion-dollar businesses by a meticulous combination of R&amp;D strengths and an exceptional management team,” said Akhil Awasthi, Managing Partner, Tata Growth PE. The Bengaluru-based biopharmaceutical company Biocon Limited had recently posted 26% fall in profit to ₹167.8 crore in the April and June quarter. SEE ALSO: <a href="https://www.businessinsider.in/science/health/news/biocon-itself-is-depressed-but-syngene-can-offer-a-shot-of-hope/articleshow/77146332.cms">Biocon shares are depressed itself but Syngene can offer a shot of hope</a> <a href="https://www.businessinsider.in/tech/news/this-is-what-amazon-google-and-facebook-had-to-say-about-india-in-their-earnings-calls/slidelist/77276228.cms">This is what Amazon, Google and Facebook had to say about India in their earnings calls</a>

Biocon’s subsidiary raises $30 million from Tata Capital – company’s shares jump by almost 2%

<ul><li>Biocon Limited share price fell over 3% despite a 14% jump in revenue between April and June 2020. </li><li>The research and development expenditure went up 35% and pushed the profit down by a quarter compared to the same time last year </li><li>However, Syngene, where Biocon owns 70% stake, has projected a double-digit revenue growth for the rest of the financial year. </li><li><a href="https://www.businessinsider.in/">Check out the latest news and updates on Business Insider.</a> </li></ul> The Bengaluru-based biopharmaceutical company Biocon Limited share price fell over 3%. Investors were disappointed by the 26% fall in profit to ₹167.8 crore ⁠— despite a 14% rise in revenue⁠— between April and June 2020 compared to a year earlier. However, the shares of its subsidiary Syngene, the integrated research, development and manufacturing company, where Biocon owns 70% stake, is up and about with gains of over 5%— the rally is close to 13% in the last two days. <div type="image" title="BIocon" msid="77146419" hostid="261"></div> The pain in Biocon Biocon, executive chairperson, <keyword id="6413985" type="PERSON" weightage="20" keywordseo="kiran-mazumdar-shaw">Kiran Mazumdar-Shaw</keyword> said, “Profitability for the quarter was impacted due to higher R&amp;D spend, lower profit share in the biosimilars business, and lower profitability in the research services segment.” The company spent 35% more on the research and development as the COVID-19 pandemic peaked. However, research services (which made for a quarter of the company’s revenue) didn’t grow at all. The revenue from the segment was ₹422 crore, unchanged from a year ago. <table style="border-width: initial; border-style: none;"></colgroup><tbody><tr><td style="border-left:solid #000000 0.9960975000000001pt;border-right:solid #000000 0.9960975000000001pt;border-bottom:solid #000000 0.9960975000000001pt;border-top:solid #000000 0.9960975000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Particulars </td><td style="border-left:solid #000000 0.9960975000000001pt;border-right:solid #000000 0.9960975000000001pt;border-bottom:solid #000000 0.9960975000000001pt;border-top:solid #000000 0.9960975000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Revenue Growth </td><td style="border-left:solid #000000 0.9960975000000001pt;border-right:solid #000000 0.9960975000000001pt;border-bottom:solid #000000 0.9960975000000001pt;border-top:solid #000000 0.9960975000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Contribution to Revenue </td></tr><tr><td style="border-left:solid #000000 0.9960975000000001pt;border-right:solid #000000 0.9960975000000001pt;border-bottom:solid #000000 0.9960975000000001pt;border-top:solid #000000 0.9960975000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Generics </td><td style="border-left:solid #000000 0.9960975000000001pt;border-right:solid #000000 0.9960975000000001pt;border-bottom:solid #000000 0.9960975000000001pt;border-top:solid #000000 0.9960975000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">16% </td><td style="border-left:solid #000000 0.9960975000000001pt;border-right:solid #000000 0.9960975000000001pt;border-bottom:solid #000000 0.9960975000000001pt;border-top:solid #000000 0.9960975000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">35.40% </td></tr><tr><td style="border-left:solid #000000 0.9960975000000001pt;border-right:solid #000000 0.9960975000000001pt;border-bottom:solid #000000 0.9960975000000001pt;border-top:solid #000000 0.9960975000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Biosimilars </td><td style="border-left:solid #000000 0.9960975000000001pt;border-right:solid #000000 0.9960975000000001pt;border-bottom:solid #000000 0.9960975000000001pt;border-top:solid #000000 0.9960975000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">19% </td><td style="border-left:solid #000000 0.9960975000000001pt;border-right:solid #000000 0.9960975000000001pt;border-bottom:solid #000000 0.9960975000000001pt;border-top:solid #000000 0.9960975000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">40.90% </td></tr><tr><td style="border-left:solid #000000 0.9960975000000001pt;border-right:solid #000000 0.9960975000000001pt;border-bottom:solid #000000 0.9960975000000001pt;border-top:solid #000000 0.9960975000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Research Services </td><td style="border-left:solid #000000 0.9960975000000001pt;border-right:solid #000000 0.9960975000000001pt;border-bottom:solid #000000 0.9960975000000001pt;border-top:solid #000000 0.9960975000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">0 </td><td style="border-left:solid #000000 0.9960975000000001pt;border-right:solid #000000 0.9960975000000001pt;border-bottom:solid #000000 0.9960975000000001pt;border-top:solid #000000 0.9960975000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">24.90% </td></tr></tbody></table> Syngene looks to return to growth COVID-19 impacted performance at Syngene with Q1 profits dropping 19% due to temporary suspension of operations on back of the lockdown; revenues were flat at `437 crores year-on-year. Margins held steady at 32%, driven by savings in raw material costs and certain operational efficiencies. The biggest takeaway was Syngene’s optimistic guidance - the management expects to see double-digit growth for the rest of the year. Future outlook from Biocon Earlier this month, the Drugs Controller General of India (DCGI) granted ‘restricted emergency use approval’ for Itolizumab, our novel anti-CD6 biologic therapy for the treatment of cytokine release syndrome (CRS) in COVID-19 patients with moderate to severe acute respiratory distress syndrome (ARDS). The company also received the <keyword id="44669" type="COMPANY" weightage="20" keywordseo="USFDA">USFDA</keyword> approval for Semglee, which will enable it to expand patient access to the Insulin Glargine through its partner Mylan. The company also targets to have at least eight biosimilars available in developed markets by the end of next financial year through its partner, — namely Trastuzumab, Pegfilgrastim, Adalimumab, Bevacizumab, Etanercept, Insulin Glargine, <keyword id="9635486" type="PERSON" weightage="20" keywordseo="insulin-aspart">Insulin Aspart</keyword> and RH-Insulin. SEE ALSO: <a href="https://www.businessinsider.in/business/corporates/news/after-google-pwc-india-declares-a-company-wide-holiday-for-its-employees-this-friday-offers-time-off-for-a-well-deserved-break/articleshow/77125627.cms">After Google, PwC India declares a company-wide holiday for its employees this Friday – offers time off for a 'well-deserved' break</a> <a href="https://www.businessinsider.in/thelife/personalities/news/mukesh-ambani-is-now-the-fifth-richest-person-in-the-world-according-to-forbes/articleshow/77105843.cms">Mukesh Ambani is now the fifth richest person in the world, according to Forbes</a> <a href="https://www.businessinsider.in/business/corporates/news/tcs-infosys-hcl-tech-dont-want-h1b-ban-but-are-pocketing-savings-while-it-lasts/articleshow/77120776.cms">The H1-B visa ban is not what Indian IT firms want⁠— but they are pocketing some savings while it lasts</a>

Biocon shares are depressed itself but Syngene can offer a shot of hope

New Delhi, May 30 () A safe Vaccine to prevent COVID-19 could take a very long time to be ready, so there is a need to deal with the pandemic for next few years and invest more in healthcare, Biocon Executive Chairperson Kiran Mazumdar-Shaw said on Saturday. She was speaking in a webinar on 'Pharma and Healthcare's New Normal: Engaging With Customers in Uncertain Times; Business Model Post-COVID-19', organised by CorpGini. "...We believe that it will take a very long time before you can actually have a safe vaccine that can be accessible to the entire country. We must understand that vaccine development is a very complex process. Shortest time taken for any vaccine is not less than 4 years," Mazumdar-Shaw said. Trying to develop vaccine in less than a year is a very daunting and almost impossible task. Vaccine development involves a large number of processes to establish the safety, efficacy and endurance of the vaccine, she added. "We need to deal with this pandemic for the next few years before we really get a reliable vaccine... We need to invest much more in healthcare. If this pandemic has exposed one ugly truth about every country, not just India, it is about the appalling state of public and primary healthcare, appalling state of under investing in healthcare," Mazumdar-Shaw said. Healthcare is a capital intensive sector, it is a skill intensive sector, it is a employment generation sector, she added. "There needs to be a very systematic data led approach to see how can we deal with the infection and keep people safe," Mazumdar-Shaw said. This is one opportunity for us to invest in healthcare infrastructure, because this what will save India and the world, she added. In similar vein, Apollo Hospitals MD Suneeta Reddy said: "This pandemic has clearly shown us the need for medical infrastructure. There needs to be an investment in healthcare, not only in infrastructure but also in skilling". Impetus given to the IT sector needs to be given to the healthcare sector to create additional infrastructure, she added. We hope the government considers healthcare as next IT sector, Reddy said. AKT BAL

You Searched For "mazumdar" and got 13 results

10 richest women in India in 2024

Ashmita Gupta

Kiran Mazumdar-Shaw to retire from Infosys board

ANI

Biocon Q1FY23 revenue up 23% at Rs 2,217 cr

IANS

Nykaa’s Falguni Nayar overtakes Kiran Mazumdar Shaw as the richest self-made Indian woman

Vaamanaa Sethi

Catch Kiran Mazumdar Shaw at the Global Trends Festival 2020, speak about unlocking India's suppressed potential

BI India Bureau

India’s second richest woman nearly doubles her wealth to $4.6 billion during the COVID-19 pandemic

Preeti Soni

India’s richest women as per Hurun list: Kiran Mazumdar Shaw and Smita Crishna on top

Rounak Jain

Biocon’s Kiran Mazumdar Shaw, who debuted in the pharma industry with two employees and $500 becomes EY World Entrepreneur of the Year 2020

Prerna Sindwani

What is gender lens investing? Sangita Reddy, Kiran Mazumdar Shaw, Nandini Piramal, and Vani Kola share their thoughts

Preeti Soni

COVID-19 will reboot world into virtual reality: Kiran Mazumdar-Shaw

PTI

Biocon’s subsidiary raises $30 million from Tata Capital – company’s shares jump by almost 2%

Sanchita Dash

Biocon shares are depressed itself but Syngene can offer a shot of hope

Navdeep Yadav

Vaccine to prevent COVID-19 will take long time to be ready: Kiran Mazumdar-Shaw

PTI

Popular Keywords

Buying Guides